You are viewing: Japan Neuromodulation Market analysis
Part of: Neuromodulation Market (Global)

The Japan Neuromodulation Market was valued at $287.6 Million in 2025 and projected to reach to $469.9 Million by 2030, representing a compound annual growth rate of 10.3%. Japan's neuromodulation market is poised for sustained expansion driven by demographic shifts and increasing neurological disease burden.

Japan Neuromodulation Market Trends and Insights

  • Japan's aging population and rising prevalence of neurological disorders are driving demand for advanced neuromodulation therapies, including spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation.
  • Japan's healthcare infrastructure and strong regulatory framework support the adoption of innovative neuromodulation devices. The Japanese market benefits from increasing healthcare expenditure and growing patient awareness of neuromodulation treatments for chronic pain and movement disorders.
  • Japan's medical device manufacturers and healthcare providers are investing in neuromodulation technology to address unmet clinical needs.
  • The 10.3% compound annual growth rate reflects Japan's commitment to advancing neurological care and improving patient outcomes through cutting-edge neuromodulation solutions..

Key Market Statistics

  • CAGR (2025-2030) 10.3% CAGR
  • Market Size, 2025 ~USD 287.6 Million
  • Forecast, 2030 ~USD 469.9 Million
  • Country Japan

Japan Neuromodulation Market Overview

Market Size & Growth :

Japan's neuromodulation market is valued at USD 287.6 million in 2025, with a robust CAGR of 10.3%, projected to reach USD 469.9 million by 2030, outpacing the global growth rate of 9.4%.

Aging Population Driver :

Japan's rapidly aging demographic is a primary catalyst for neuromodulation adoption, with increasing prevalence of age-related neurological conditions including Parkinson's disease, essential tremor, and chronic pain syndromes.

Advanced Therapy Adoption :

Spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation technologies are gaining significant traction in Japan's healthcare system, supported by improved reimbursement policies and clinical evidence.

Healthcare Infrastructure Strength :

Japan's advanced healthcare infrastructure, high medical device adoption rates, and strong regulatory framework position it as a leading market for innovative neuromodulation solutions in Asia-Pacific.

Japan Neuromodulation Market Dynamics

  • The aging population, combined with rising healthcare expenditure and improved patient awareness, creates favorable conditions for market growth.
  • Healthcare providers are increasingly adopting advanced neuromodulation therapies as first-line and adjunctive treatments for chronic pain and movement disorders. Government initiatives supporting medical device innovation and favorable reimbursement trends are expected to accelerate market penetration.
  • Japanese manufacturers are investing in R&D to develop next-generation neuromodulation devices tailored to local patient needs.
  • Strategic partnerships between domestic and international companies will further enhance market accessibility and drive competitive pricing, benefiting patients and healthcare systems across Japan..

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Japan's neuromodulation market is valued at USD 287.6 million in 2025 and is expected to reach USD 469.9 million by 2030, representing a 10.3% CAGR.
      • Japan's aging demographic and increasing prevalence of chronic neurological conditions are primary drivers of neuromodulation market expansion.
      • Japan's advanced healthcare infrastructure and regulatory environment facilitate rapid adoption of innovative neuromodulation technologies.
      • Japan's market growth is supported by rising healthcare spending and growing patient and physician awareness of neuromodulation treatment benefits.

      Neuromodulation Market Report Scope

      Report Metric Details
      Base Year 2025
      Fastest Growing Segment DEEP BRAIN STIMULATION (Stimulation Type)
      Forecast Period 2025–2030
      Growth Rate CAGR of 9.4% from 2025 to 2030
      Largest Segment INTERNAL NEUROMODULATION (Technology)
      Market Size Base Year (Billions) ~USD 6.82 (2025)
      Revenue Forecast (Billions) ~USD 10.68 (2030)
      Segments Covered Technology, Stimulation Type, Application, End User

      Japan Neuromodulation Market Report Segmentation

      4 segment dimensions are covered across the global market.

      By Technology

      • External Neuromodulation
      • Internal Neuromodulation

      By Stimulation Type

      • Deep Brain Stimulation
      • Gastric Electrical Stimulation
      • Other Stimulation Types
      • Respiratory Electrical Stimulation
      • Sacral Nerve Stimulation
      • Spinal Cord Stimulation
      • Transcranial Magnetic Stimulation
      • Transcutaneous Electrical Nerve Stimulation
      • Vagus Nerve Stimulation

      By Application

      • Chronic Pain
      • Depression
      • Epilepsy
      • Failed Back Surgery Syndrome
      • Fecal Incontinence
      • Gastroparesis
      • Ischemia
      • Migraine
      • Obesity
      • Other Deep Brain Stimulation Applications
      • Other Transcutaneous Electrical Nerve Stimulation Applications
      • Other Vagus Nerve Stimulation Applications
      • Parkinson’S Disease
      • Treatment-Resistant Depression
      • Tremor
      • Urine Incontinence

      By End User

      • Clinics & Physiotherapy Centers
      • Hospitals & Ambulatory Surgery Centers
      • Other End Users

      Target Audience

      • Medical Device Manufacturers : Neuromodulation device companies seeking to expand or establish presence in Japan need market sizing, competitive analysis, and regulatory insights to develop localized commercialization strategies.
      • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in Japan's healthcare sector require detailed market forecasts, growth drivers, and competitive dynamics to assess portfolio companies and acquisition targets.
      • Hospital & Healthcare Systems : Japanese healthcare providers and hospital networks need market intelligence on neuromodulation adoption trends, reimbursement policies, and clinical outcomes to inform procurement and service expansion decisions.
      • Pharmaceutical & Biotech Companies : Companies developing neuromodulation-adjacent therapies require market context on Japan's neurological disease burden, treatment paradigms, and competitive landscape for strategic positioning.
      • Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients need comprehensive Japan-specific data, forecasts, and insights to support client advisory work and market analysis reports.

      Key Companies in the Japan Neuromodulation Market

      CompanyHQOwnershipStrongest segments
      BIOGENUnited StatesPublic CompanyInternal neuromodulation (implanted SCS/DBS/VNS-aligned adjacencies),External neuromodulation (non-invasive stimulation adjacencies),Spinal cord stimulation–linked care pathways,
      MEDTRONICIrelandPublic CompanyInternal neuromodulation – Spinal Cord Stimulation,Internal neuromodulation – Deep Brain Stimulation,Internal neuromodulation – Vagus Nerve and Other Implants,
      BOSTON SCIENTIFIC CORPORATIONUnited StatesPublic CompanyInternal neuromodulation systems (implantable SCS, DBS, VNS),External neuromodulation systems and accessories,Radiofrequency and intraosseous nerve ablation for pain,
      ABBOTTUnited StatesPublic CompanyInternal neuromodulation – Spinal cord stimulation,Internal neuromodulation – Deep brain stimulation,Internal neuromodulation – Vagus nerve and other implants,
      LIVANOVA PLCUnited KingdomPublic CompanyInternal Vagus Nerve Stimulation for Epilepsy,Internal Vagus Nerve Stimulation for Depression,Other Neuromodulation (including aura6000 OSA development),
      NEVRO CORP.United StatesPrivate CompanyInternal SCS systems (Senza, Senza II, Senza Omnia, HFX iQ IPG),Surgical and percutaneous leads,Trial stimulators, remotes, and HFX App / digital,
      NEUROPACE, INC.United StatesPublic CompanyInternal neuromodulation – Deep brain–adjacent epilepsy (RNS neurostimulator + leads),Digital platforms and data services (nSight, patient data management, physician tablet ecosystem),Accessories and disposables (non-implantable components, remote monitors, ancillary hardware),
      BIOVENTUSUnited StatesPublic CompanyExternal / Peripheral Neuromodulation (Stimrouter, TalisMann, Exogen-related pain pathways),Surgical Ultrasonic Systems (neXus, BoneScalpel, SonaStar, SonicOne) in Neuro and Spine,Bone Graft Substitutes and Restorative Therapies in Neuro/Spine Settings,
      ELECTROCORE, INC.United StatesPublic CompanyExternal VNS – gammaCore (migraine, cluster, other headache),General wellness nVNS – Truvaga 350 and Truvaga Plus,Human performance and other non-invasive bioelectronic therapies (TAC-STIM, chronic pain, performance),
      HELIUS MEDICAL TECHNOLOGIES, INC.United StatesPublic CompanyExternal neuromodulation – PoNS for gait and balance deficits,Other neurological wellness and digital programs,Other digital asset / treasury-related activities,
      NEURONETICSUnited StatesPublic CompanyExternal neuromodulation – TMS for Depression (Clinics & Psychiatrist Offices),External neuromodulation – Hospital-based TMS Programs,Other neuromodulation applications (Ischemia, Epilepsy, Obesity; emerging geographies and pilots),
      NEUROSIGMA, INC.United StatesPrivate CompanyExternal Neuromodulation – Trigeminal Nerve Stimulation (eTNS/TNS) for ADHD,External Neuromodulation – TNS for Epilepsy and LGS (early commercialization),External Neuromodulation – TNS for Depression, PTSD, TBI,

      BIOGEN

      Biogen is a United States-based biotechnology company founded in 1978 with 7,500 employees. Operating as a public company, Biogen focuses on developing and commercializing therapies for neurological and neurodegenerative diseases.

      MEDTRONIC

      Medtronic is a multinational medical device company headquartered in Ireland, founded in 1949 with 95,000 employees. As a public company, Medtronic develops and manufactures a broad range of medical devices and therapies across multiple therapeutic areas.

      BOSTON SCIENTIFIC CORPORATION

      Boston Scientific Corporation is a United States-based medical device company founded in 1979 with 59,000 employees. The public company designs, manufactures, and markets medical devices used in interventional medical specialties.

      ABBOTT

      Abbott is a diversified healthcare company founded in the United States in 1888 with 115,000 employees. Operating as a public company, Abbott develops pharmaceuticals, medical devices, diagnostics, and nutritional products.

      LIVANOVA PLC

      LivaNova PLC is a United Kingdom-based medical device company founded in 2015 with 3,300 employees. The public company specializes in neuromodulation and cardiac surgery solutions.

      NEVRO CORP.

      Nevro Corp. is a United States-based medical device company founded in 2006 with 1,099 employees. Operating as a private company, Nevro develops neuromodulation therapies for chronic pain management.

      NEUROPACE, INC.

      NeuroPace, Inc. is a United States-based medical device company founded in 1997 with 220 employees. The public company develops and commercializes neurostimulation technology for neurological disorders.

      BIOVENTUS

      BioVentus is a United States-based medical device company founded in 2011 with 940 employees. Operating as a public company, BioVentus focuses on orthopedic and regenerative medicine solutions.

      ELECTROCORE, INC.

      ElectroCore, Inc. is a United States-based bioelectronic medicine company founded in 2005 with 83 employees. The public company develops non-invasive vagus nerve stimulation therapies for various conditions.

      HELIUS MEDICAL TECHNOLOGIES, INC.

      Helius Medical Technologies, Inc. is a United States-based medical device company with 21 employees. Operating as a public company, Helius develops neurorehabilitation technologies.

      NEURONETICS

      Neuronetics is a United States-based medical device company founded in 2001 with 658 employees. The public company develops and commercializes neuromodulation therapies for psychiatric and neurological conditions.

      NEUROSIGMA, INC.

      NeuroSigma, Inc. is a United States-based neurotechnology company founded in 2008 with 11 employees. Operating as a private company, NeuroSigma develops bioelectronic therapies for neurological disorders.

      Reasons to Buy this Report

      • Market-Specific Growth Insights : Gain detailed understanding of Japan's 10.3% CAGR trajectory and identify high-growth segments within spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation categories specific to the Japanese market.
      • Demographic & Clinical Opportunity Analysis : Understand how Japan's aging population and rising neurological disorder prevalence create unique market opportunities, with actionable insights on patient demographics and disease prevalence patterns.
      • Competitive Landscape & Market Positioning : Access comprehensive competitive intelligence on Japanese and international neuromodulation manufacturers, market share dynamics, and strategic positioning to inform entry or expansion strategies.
      • Reimbursement & Regulatory Framework : Obtain detailed analysis of Japan's healthcare reimbursement policies, regulatory pathways, and government initiatives supporting neuromodulation adoption to navigate market entry and commercialization strategies.
      • Investment & Partnership Opportunities : Identify strategic partnership opportunities, acquisition targets, and investment prospects within Japan's neuromodulation ecosystem, supported by market sizing and growth forecasts through 2030.

      Frequently asked questions

      What is the current size of Japan's neuromodulation market?

      Japan's neuromodulation market was valued at USD 287.6 million in 2025 and is projected to grow to USD 469.9 million by 2030.

      What is the expected growth rate for Japan's neuromodulation market?

      Japan's neuromodulation market is expected to grow at a compound annual growth rate (CAGR) of 10.3% from 2025 to 2030.

      What factors are driving growth in Japan's neuromodulation market?

      Key growth drivers in Japan include an aging population, rising prevalence of neurological disorders, increased healthcare expenditure, and growing awareness of neuromodulation therapies.

      Which neuromodulation therapies are most prevalent in Japan?

      Japan's market includes spinal cord stimulation, deep brain stimulation, and peripheral nerve stimulation, with adoption driven by chronic pain and movement disorder treatment needs.

      How does Japan's regulatory environment support neuromodulation market growth?

      Japan's strong regulatory framework and advanced healthcare infrastructure facilitate the approval and adoption of innovative neuromodulation devices and therapies.

      RESEARCH METHODOLOGY

      The study involved key activities in estimating the current market size for the neuromodulation industry. Exhaustive secondary research was conducted to gather information on the neuromodulation sector. The next step was to validate these findings, assumptions, and estimates with industry experts across the value chain through primary research. Different methods, such as top-down and bottom-up approaches, were used to determine the total market size. Subsequently, market segmentation and data triangulation procedures were applied to estimate the market size of segments and subsegments within the neuromodulation market.

      The four steps involved in estimating the market size are:

      Secondary Research

      The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, investor presentations, SEC filings of companies and publications from government sources [such as National Institutes of Health (NIH), US FDA, US Census Bureau, World Health Organization (WHO), , Global Burden of Disease Study, and Centers for Medicare and Medicaid Services (CMS) were referred to identify and collect information for the global neuromodulation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to gather qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology and innovation directors, and other key executives from various companies and organizations in the neuromodulation market. The primary sources from the demand side include biotechnology companies, CROs, pharmacies, medical device companies, and research academics and universities. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on important industry trends and key market dynamics.

      The following is a breakdown of the primary respondents:

      Neuromodulation Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      For the global market value, annual revenues were calculated based on revenue mapping of major product manufacturers and OEMs active in the worldwide neuromodulation market. All key service providers were identified at the global and/or country/regional level. Revenue mapping for the relevant business segments/sub-segments was performed for the major players. The global neuromodulation market was split into various segments and sub-segments based on:

      • List of major players operating in the products market at the regional and/or country level
      • Product mapping of neuromodulation providers at the regional and/or country level
      • Mapping of annual revenue generated by listed major players from neuromodulation (or the nearest reported business unit/product category)
      • Extrapolation of the revenue mapping of the listed major players to derive the global market value of the respective segments/subsegments
      • Summation of the market value of all segments/subsegments to arrive at the global neuromodulation market

      The above-mentioned data was consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

      The research methodology used to estimate the market size includes the following:

      Neuromodulation Market

      Data Triangulation

      After determining the overall market size using the process described above, the total market was divided into several segments. To finalize the market engineering process and obtain precise statistics for all segments and subsegments, data triangulation and market breakdown methods were employed where applicable. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Neuromodulation is a medical technology that modifies nerve activity by delivering targeted stimulation to specific areas of the body. It covers a broad range of therapies, from managing chronic pain—which is the most common use—to treating neurological and urological disorders, as well as movement disorders like Parkinson’s disease. By directly affecting neural pathways, neuromodulation can restore function, alleviate symptoms, and enhance quality of life, with ongoing innovations making it a rapidly growing field in modern medicine healthcare.

      Stakeholders

      • Neuromodulation and related device manufacturing companies
      • Equipment manufacturers
      • Suppliers and distributors of neuromodulation devices
      • Healthcare service providers
      • Teaching hospitals and academic medical centers (AMCs)
      • Health insurance players
      • Research and consulting firms
      • Medical research institutes
      • Healthcare institutions/providers (hospitals, medical groups, physicians’ practices, diagnostic centers, and outpatient clinics)
      • Venture capitalists
      • Community centers

      Report Objectives

      • To define, describe, segment, and forecast the global neuromodulation market by technology, stimulation type, application, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall neuromodulation market
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
      • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI/Gen AI on the market, along with the macroeconomic outlook for each region

      Get the Full Neuromodulation Market Report

      Full forecast, segment splits, and company analysis for all Neuromodulation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status